

# Neutralizing monoclonal antibodies for treatment of COVID-19

Nature Reviews Immunology

21, 382-393

DOI: [10.1038/s41577-021-00542-x](https://doi.org/10.1038/s41577-021-00542-x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Immunotherapeutics (II). <i>Farmacist Ro</i> , 2021, 3, 7.	0.0	0
2	Standardized Two-Step Testing of Antibody Activity in COVID-19 Convalescent Plasma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
5	The Relevance of Monoclonal Antibodies in the Treatment of COVID-19. <i>Vaccines</i> , 2021, 9, 557.	2.1	10
6	Antiviral treatment selection for SARS-CoV-2 pneumonia. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 985-992.	1.0	4
11	Is SARS-CoV-2 Neutralized More Effectively by IgM and IgA than IgG Having the Same Fab Region?. <i>Pathogens</i> , 2021, 10, 751.	1.2	12
12	Stabilization of the SARS-CoV-2 Spike Receptor-Binding Domain Using Deep Mutational Scanning and Structure-Based Design. <i>Frontiers in Immunology</i> , 2021, 12, 710263.	2.2	32
15	Le traitement de support de la COVID-19 et sa malchance de porter le nom de probiotique. <i>HEGEL - HEpato-GastroEntérologie Libérale</i> , 2021, N° 2, 126-131.	0.0	0
17	Covid-19 pandemic: all possible effective solutions to eradicate the problem. Cross-sectional analysis of clinical, socioeconomic, political and psychological profiles. <i>Archives of Community Medicine and Public Health</i> , 2021, , 099-110.	0.1	3
18	Statins in COVID-19 Therapy. <i>Life</i> , 2021, 11, 565.	1.1	3
20	Neutralizing Monoclonal Antibody Treatment Reduces Hospitalization for Mild and Moderate Coronavirus Disease 2019 (COVID-19): A Real-World Experience. <i>Clinical Infectious Diseases</i> , 2022, 74, 1063-1069.	2.9	57
21	SARS-CoV-2 Antiviral Therapy. <i>Clinical Microbiology Reviews</i> , 2021, 34, e0010921.	5.7	64
22	The Rise of SARS-CoV-2 Variants and the Role of Convalescent Plasma Therapy for Management of Infections. <i>Life</i> , 2021, 11, 734.	1.1	34
23	Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. <i>Nature</i> , 2021, 596, 276-280.	18.7	1,803
26	Identification of Human SARS-CoV-2 Monoclonal Antibodies from Convalescent Patients Using EBV Immortalization. <i>Antibodies</i> , 2021, 10, 26.	1.2	1
27	A novel IgM intranasal intervention against SARS-CoV-2. <i>Antibody Therapeutics</i> , 2021, 4, 171-174.	1.2	4
30	COVID-19: Failure of the DisCoVeRy Clinical Trial, and Now "New Hopes?". <i>Pharmaceuticals</i> , 2021, 14, 664.	1.7	3
32	SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data. <i>Eurosurveillance</i> , 2021, 26, .	3.9	31
33	An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 1403-1414.	2.5	14

#	ARTICLE	IF	CITATIONS
34	Use of Monoclonal Antibody to Treat COVID-19 in Children and Adolescents: Risk of Abuse of Prescription and Exacerbation of Health Inequalities. <i>Pharmaceuticals</i> , 2021, 14, 673.	1.7	4
35	SARS-CoV-2 spike protein: pathogenesis, vaccines, and potential therapies. <i>Infection</i> , 2021, 49, 855-876.	2.3	61
37	Coadministration of Anti-Viral Monoclonal Antibodies With Routine Pediatric Vaccines and Implications for Nirsevimab Use: A White Paper. <i>Frontiers in Immunology</i> , 2021, 12, 708939.	2.2	8
39	Case Report: Severe COVID-19 in a Kidney Transplant Recipient Without Humoral Response to SARS-CoV-2 mRNA Vaccine Series. <i>Transplantation Direct</i> , 2021, 7, e743.	0.8	3
40	Case Report: Convalescent Plasma Therapy Induced Anti-SARS-CoV-2 T Cell Expansion, NK Cell Maturation and Virus Clearance in a B Cell Deficient Patient After CD19 CAR T Cell Therapy. <i>Frontiers in Immunology</i> , 2021, 12, 721738.	2.2	5
41	What Binds Cationic Photosensitizers Better: Brownian Dynamics Reveals Key Interaction Sites on Spike Proteins of SARS-CoV, MERS-CoV, and SARS-CoV-2. <i>Viruses</i> , 2021, 13, 1615.	1.5	8
42	Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement. <i>Journal of Neuroimmunology</i> , 2021, 357, 577627.	1.1	33
43	Biopharmaceutics 4.0, Advanced Pre-Clinical Development of mRNA-Encoded Monoclonal Antibodies to Immunosuppressed Murine Models. <i>Vaccines</i> , 2021, 9, 890.	2.1	4
44	A Narrative Review of the Clinical Practicalities of Bamlanivimab and Etesevimab Antibody Therapies for SARS-CoV-2. <i>Infectious Diseases and Therapy</i> , 2021, 10, 1933-1947.	1.8	29
45	Clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe COVID-19. <i>Respiratory Investigation</i> , 2021, 59, 799-803.	0.9	24
47	Novel strategies for the development of hand, foot, and mouth disease vaccines and antiviral therapies. <i>Expert Opinion on Drug Discovery</i> , 2022, 17, 27-39.	2.5	12
48	Murine Monoclonal Antibodies against the Receptor Binding Domain of SARS-CoV-2 Neutralize Authentic Wild-Type SARS-CoV-2 as Well as B.1.1.7 and B.1.351 Viruses and Protect <i>In Vivo</i> in a Mouse Model in a Neutralization-Dependent Manner. <i>MBio</i> , 2021, 12, e0100221.	1.8	7
49	Efficacy and safety of hydroxychloroquine as pre-and post-exposure prophylaxis and treatment of COVID-19: A systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials.. <i>The Lancet Regional Health Americas</i> , 2021, 2, 100062.	1.5	33
50	Better late than never: eventual seroconversion against SARS-CoV-2 in a kidney transplant recipient after repeated immune challenge and monoclonal antibody therapy. <i>Kidney International</i> , 2021, 100, 1131-1132.	2.6	3
51	B cell depletion in immune-mediated rheumatic diseases and coronavirus disease 2019 (COVID-19). <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2021, 59, 384-393.	0.2	12
52	Filovirus Neutralising Antibodies: Mechanisms of Action and Therapeutic Application. <i>Pathogens</i> , 2021, 10, 1201.	1.2	9
53	Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy. <i>Nature</i> , 2021, 599, 465-470.	13.7	129
54	Antibody therapy for COVID-19. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2021, 21, 553-558.	1.1	17

#	ARTICLE	IF	CITATIONS
55	COVID-19 pandemic: lessons learned from more than a century of pandemics and current vaccine development for pandemic control. <i>International Journal of Infectious Diseases</i> , 2021, 112, 300-317.	1.5	21
56	Heterologous Hyperimmune Polyclonal Antibodies Against SARS-CoV-2: A Broad Coverage, Affordable, and Scalable Potential Immunotherapy for COVID-19. <i>Frontiers in Medicine</i> , 2021, 8, 743325.	1.2	10
57	How many animals are used for SARS-CoV-2 research?. <i>EMBO Reports</i> , 2021, 22, e53751.	2.0	6
58	Combination therapies for COVID-19: An overview of the clinical trials landscape. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 1590-1597.	1.1	18
60	Ronapreve for prophylaxis and treatment of covid-19. <i>BMJ, The</i> , 2021, 374, n2136.	3.0	12
61	Serum IgG4 level predicts COVID-19 related mortality. <i>European Journal of Internal Medicine</i> , 2021, 93, 107-109.	1.0	21
62	Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis. <i>BMJ, The</i> , 2021, 374, n2231.	3.0	59
63	Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain. <i>Cell Reports</i> , 2021, 37, 109822.	2.9	35
64	A look into the future of the COVID-19 pandemic in Europe: an expert consultation. <i>Lancet Regional Health - Europe, The</i> , 2021, 8, 100185.	3.0	72
67	The challenges with developing therapeutic monoclonal antibodies for pandemic application. <i>Expert Opinion on Drug Discovery</i> , 2022, 17, 5-8.	2.5	2
68	A tetrameric ACE2 protein broadly neutralizes SARS-CoV-2 spike variants of concern with elevated potency. <i>Antiviral Research</i> , 2021, 194, 105147.	1.9	11
69	Mathematical modelling of SARS-CoV-2 infection of human and animal host cells reveals differences in the infection rates and delays in viral particle production by infected cells. <i>Journal of Theoretical Biology</i> , 2021, 531, 110895.	0.8	5
70	Animal models of SARS-CoV-2 and COVID-19 for the development of prophylactic and therapeutic interventions. , 2021, 228, 107931.		18
71	Monoclonal Antibody. , 2021, , .		0
73	Detección de anticuerpos neutralizantes en profesionales de la salud vacunados contra el SARS-CoV-2. <i>Horizonte Médico</i> , 2021, 21, e1539.	0.1	1
74	Global Prevalence of Adaptive and Prolonged Infections™ Mutations in the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein. <i>Viruses</i> , 2021, 13, 1974.	1.5	9
75	Genomics serology to inform therapies and vaccines for arthritogenic alphaviruses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	0
76	How Antibodies Recognize Pathogenic Viruses: Structural Correlates of Antibody Neutralization of HIV-1, SARS-CoV-2, and Zika. <i>Viruses</i> , 2021, 13, 2106.	1.5	7

#	ARTICLE	IF	CITATIONS
77	SARS-CoV-2 Vaccine Induced Atypical Immune Responses in Antibody Defects: Everybody Does their Best. <i>Journal of Clinical Immunology</i> , 2021, 41, 1709-1722.	2.0	68
78	No crossreactivity of anti-SARS-CoV-2 spike protein antibodies with Syncytin-1. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2566-2568.	4.8	18
80	Molecular rationale for SARS-CoV-2 spike circulating mutations able to escape bamlanivimab and etesevimab monoclonal antibodies. <i>Scientific Reports</i> , 2021, 11, 20274.	1.6	33
81	Evaluation of COVID-19 vaccine response in patients with cancer: An interim analysis. <i>European Journal of Cancer</i> , 2021, 159, 259-274.	1.3	50
82	Rapid Proliferation of Pandemic Research: Implications for Dual-Use Risks. <i>MBio</i> , 2021, 12, e0186421.	1.8	9
83	A Patent Review on SARS Coronavirus Main Protease (3CL <sup>pro</sup> ) Inhibitors. <i>ChemMedChem</i> , 2022, 17, e202100576.	1.6	23
84	Xeno-Nucleic Acid (XNA) 2'-Fluoro-Arabino Nucleic Acid (FANA) Aptamers to the Receptor-Binding Domain of SARS-CoV-2 S Protein Block ACE2 Binding. <i>Viruses</i> , 2021, 13, 1983.	1.5	40
85	Mechanisms of Lung Injury Induced by SARS-CoV-2 Infection. <i>Physiology</i> , 2022, 37, 88-100.	1.6	18
87	Comparative effectiveness of pharmacological interventions on mortality and the average length of hospital stay of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 585-609.	2.0	5
90	A PENNdemc Year in Review. <i>Advances in Molecular Pathology</i> , 2021, 4, 205-216.	0.2	2
91	IL-1 and IL-6 inhibition affects the neutralising activity of anti-SARS-CoV-2 antibodies in patients with COVID-19. <i>Lancet Rheumatology</i> , The, 2021, 3, e829-e831.	2.2	13
92	High Individual Heterogeneity of Neutralizing Activities against the Original Strain and Nine Different Variants of SARS-CoV-2. <i>Viruses</i> , 2021, 13, 2177.	1.5	21
93	A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load. <i>Clinical Infectious Diseases</i> , 2022, 75, e440-e449.	2.9	46
94	SARS-CoV-2 Delta (B.1.617.2) Variant: A Unique T478K Mutation in Receptor Binding Motif (RBM) of Spike Gene. <i>Immune Network</i> , 2021, 21, e32.	1.6	51
95	Vaccine-Induced Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response and the Path to Accelerating Development (Determining a Correlate of Protection). <i>Clinics in Laboratory Medicine</i> , 2022, 42, 111-128.	0.7	8
96	The concentrated antibody from convalescent plasma balanced the dysfunctional immune responses in patients with critical COVID-19. <i>Clinical and Translational Medicine</i> , 2021, 11, e571.	1.7	1
97	Single B cell technologies for monoclonal antibody discovery. <i>Trends in Immunology</i> , 2021, 42, 1143-1158.	2.9	63
98	Profiling Antibody Response Patterns in COVID-19: Spike S1-Reactive IgA Signature in the Evolution of SARS-CoV-2 Infection. <i>Frontiers in Immunology</i> , 2021, 12, 772239.	2.2	18

#	ARTICLE	IF	CITATIONS
99	Myeloid dysregulation and therapeutic intervention in COVID-19. <i>Seminars in Immunology</i> , 2021, 55, 101524.	2.7	9
100	Structural Biology of Nanobodies against the Spike Protein of SARS-CoV-2. <i>Viruses</i> , 2021, 13, 2214.	1.5	16
101	SARS-CoV-2 and HIV-1: Should HIV-1-Infected Individuals in Sub-Saharan Africa Be Considered a Priority Group for the COVID-19 Vaccines?. <i>Frontiers in Immunology</i> , 2021, 12, 797117.	2.2	4
102	Racial/Ethnic Disparities in Health Care Setting Choice for Adults Seeking Severe Acute Respiratory Syndrome Coronavirus 2 Testing. <i>Medical Care</i> , 2022, 60, 3-12.	1.1	9
103	Murine monoclonal antibodies against RBD of the SARS-CoV-2 spike protein as useful analytical tools for subunit vaccine development and clinical trials. <i>Journal of Immunological Methods</i> , 2022, 500, 113195.	0.6	4
104	Anti-SARS-CoV-1 and $\alpha^2$ nanobody engineering towards avidity-inspired therapeutics. <i>Nano Today</i> , 2022, 42, 101350.	6.2	16
106	Time-Dependent COVID-19 Mortality in Patients With Cancer. <i>JAMA Oncology</i> , 2022, 8, 114.	3.4	50
107	Molecular insights into receptor binding energetics and neutralization of SARS-CoV-2 variants. <i>Nature Communications</i> , 2021, 12, 6977.	5.8	55
108	Effectiveness of monoclonal antibody therapy for COVID-19 patients using a risk scoring system. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 352-355.	0.8	6
110	A stem-loop RNA RIG-I agonist protects against acute and chronic SARS-CoV-2 infection in mice. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	46
111	MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants. <i>Frontiers in Immunology</i> , 2021, 12, 778829.	2.2	2
112	Evolution of spike mutations following antibody treatment in two immunocompromised patients with persistent COVID-19 infection. <i>Journal of Medical Virology</i> , 2022, 94, 1241-1245.	2.5	22
113	Coronavirus Disease (COVID-19) Control between Drug Repurposing and Vaccination: A Comprehensive Overview. <i>Vaccines</i> , 2021, 9, 1317.	2.1	35
114	Coronavirus Disease 2019: Clinics, Treatment, and Prevention. <i>Frontiers in Microbiology</i> , 2021, 12, 761887.	1.5	21
116	Monoclonal Antibodies against Nucleocapsid Protein of SARS-CoV-2 Variants for Detection of COVID-19. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12412.	1.8	15
118	The emergence of SARS-CoV-2 variants threatens to decrease the efficacy of neutralizing antibodies and vaccines. <i>Biochemical Society Transactions</i> , 2021, 49, 2879-2890.	1.6	16
120	Pharmacokinetics of high-titer anti-SARS-CoV-2 human convalescent plasma in high-risk children. <i>JCI Insight</i> , 2022, 7, .	2.3	12
121	Rapid structural discrimination of IgG antibodies by multicharge-state collision-induced unfolding. <i>RSC Advances</i> , 2021, 11, 36502-36510.	1.7	1

#	ARTICLE	IF	CITATIONS
122	Clinical severe acute respiratory syndrome coronavirus 2 isolation and antiviral testing. <i>Antiviral Chemistry and Chemotherapy</i> , 2021, 29, 204020662110610.	0.3	4
123	Neutralizing antibody: a savior in the Covid-19 disease. <i>Molecular Biology Reports</i> , 2022, 49, 2465-2474.	1.0	18
125	A systematic review of Vaccine Breakthrough Infections by SARS-CoV-2 Delta Variant. <i>International Journal of Biological Sciences</i> , 2022, 18, 889-900.	2.6	40
126	An improved iliac lymph node method for production of monoclonal antibodies. <i>Development Growth and Differentiation</i> , 2022, 64, 38-47.	0.6	5
127	Editorial: Obesity, metabolic phenotypes and COVID-19. <i>Metabolism: Clinical and Experimental</i> , 2022, 128, 155121.	1.5	20
128	Development of plant-made monoclonal antibodies against viral infections. <i>Current Opinion in Virology</i> , 2022, 52, 148-160.	2.6	19
129	Virtual screening and in vitro validation of natural compound inhibitors against SARS-CoV-2 spike protein. <i>Bioorganic Chemistry</i> , 2022, 119, 105574.	2.0	10
130	MS and NMOSD during the pandemic COVID-19 - what have we already learnt?. <i>Neurologie Pro Praxi</i> , 2021, 22, 289-294.	0.0	0
131	Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. <i>Nature</i> , 2022, 602, 671-675.	13.7	1,202
132	Clonal Wars: Monoclonal Antibodies Against Infectious Pathogens. <i>DNA and Cell Biology</i> , 2022, 41, 34-37.	0.9	2
133	Memory Gaps in America: Mutational and Immunoinformatic Analysis of Evolving SARS-CoV-2 Variants of Concern and Interest. <i>ImmunoHorizons</i> , 2022, 6, 1-7.	0.8	0
134	Experience of Rwanda on COVID-19 Case Management: From Uncertainties to the Era of Neutralizing Monoclonal Antibodies. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 1023.	1.2	3
135	Potential therapeutic options for COVID-19: an update on current evidence. <i>European Journal of Medical Research</i> , 2022, 27, 6.	0.9	85
136	Searching for escape-resistant anti-SARS-CoV-2 neutralizing antibodies. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	2
137	Clinical characteristics and treatment outcomes of SARS-CoV-2 delta variant outbreak, Pingtung, Taiwan, June 2021. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 1767-1772.	0.8	7
138	An insight into SARS-CoV-2 structure, pathogenesis, target hunting for drug development and vaccine initiatives. <i>RSC Medicinal Chemistry</i> , 2022, 13, 647-675.	1.7	3
139	Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology. <i>Journal of Hematology and Oncology</i> , 2022, 15, 5.	6.9	30
140	In Silico Analyses on the Comparative Potential of Therapeutic Human Monoclonal Antibodies Against Newly Emerged SARS-CoV-2 Variants Bearing Mutant Spike Protein. <i>Frontiers in Immunology</i> , 2021, 12, 782506.	2.2	24

#	ARTICLE	IF	CITATIONS
141	Quantum optical immunoassay: upconversion nanoparticle-based neutralizing assay for COVID-19. <i>Scientific Reports</i> , 2022, 12, 1263.	1.6	8
142	Activation of TCA cycle restrains virus-metabolic hijacking and viral replication in mouse hepatitis virus-infected cells. <i>Cell and Bioscience</i> , 2022, 12, 7.	2.1	11
143	Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines. <i>Pharmacological Reviews</i> , 2022, 74, 313-339.	7.1	9
144	Tafenoquine and its derivatives as inhibitors for the severe acute respiratory syndrome coronavirus 2. <i>Journal of Biological Chemistry</i> , 2022, 298, 101658.	1.6	12
146	Preclinical Evaluation of Chicken Egg Yolk Antibody (IgY) Anti-RBD Spike SARS-CoV-2 as a Candidate for Passive Immunization against COVID-19. <i>Vaccines</i> , 2022, 10, 128.	2.1	8
147	Spike-Dependent Opsonization Indicates Both Dose-Dependent Inhibition of Phagocytosis and That Non-Neutralizing Antibodies Can Confer Protection to SARS-CoV-2. <i>Frontiers in Immunology</i> , 2021, 12, 808932.	2.2	34
149	A pandemic-enabled comparison of discovery platforms demonstrates a naïve antibody library can match the best immune-sourced antibodies. <i>Nature Communications</i> , 2022, 13, 462.	5.8	17
150	Structural Biology Illuminates Molecular Determinants of Broad Ebolavirus Neutralization by Human Antibodies for Pan-Ebolavirus Therapeutic Development. <i>Frontiers in Immunology</i> , 2021, 12, 808047.	2.2	4
151	Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection. <i>Journal of Biomedical Science</i> , 2022, 29, 1.	2.6	144
152	Omicron: A Heavily Mutated SARS-CoV-2 Variant Exhibits Stronger Binding to ACE2 and Potently Escapes Approved COVID-19 Therapeutic Antibodies. <i>Frontiers in Immunology</i> , 2021, 12, 830527.	2.2	165
153	The impact of neutralizing monoclonal antibodies on the outcomes of COVID-19 outpatients: A systematic review and meta-analysis of randomized controlled trials. <i>Journal of Medical Virology</i> , 2022, 94, 2222-2229.	2.5	43
154	Standardized two-step testing of antibody activity in COVID-19 convalescent plasma. <i>iScience</i> , 2022, 25, 103602.	1.9	6
156	Implication of the emergence of the delta (B.1.617.2) variants on vaccine effectiveness. <i>Infection</i> , 2022, , 1.	2.3	15
157	MetaLogo: a heterogeneity-aware sequence logo generator and aligner. <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	6
158	Safety and tolerability of hydroxychloroquine in health care workers and first responders for the prevention of COVID-19: WHIP COVID-19 Study. <i>International Journal of Infectious Diseases</i> , 2022, 116, 167-173.	1.5	9
159	Versatile role of ACE2-based biosensors for detection of SARS-CoV-2 variants and neutralizing antibodies. <i>Biosensors and Bioelectronics</i> , 2022, 203, 114034.	5.3	30
160	Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic. <i>Environmental Research</i> , 2022, 209, 112816.	3.7	189
161	Machine Learning at the Interface of Polymer Science and Biology: How Far Can We Go?. <i>Biomacromolecules</i> , 2022, 23, 576-591.	2.6	10



#	ARTICLE	IF	CITATIONS
162	Symptoms and risk factors for hospitalization of COVID-19 presented in primary care. Wiener Klinische Wochenschrift, 2022, 134, 335-343.	1.0	4
163	Human SUMOylation Pathway Is Critical for Influenza B Virus. Viruses, 2022, 14, 314.	1.5	0
164	Therapeutics for COVID-19 and post COVID-19 complications: An update. Current Research in Pharmacology and Drug Discovery, 2022, 3, 100086.	1.7	55
165	Human inhalable antibody fragments neutralizing SARS-CoV-2 variants for COVID-19 therapy. Molecular Therapy, 2022, 30, 1979-1993.	3.7	15
166	Parallel profiling of antigenicity alteration and immune escape of SARS-CoV-2 Omicron and other variants. Signal Transduction and Targeted Therapy, 2022, 7, 42.	7.1	25
167	Preclinical Immune Response and Safety Evaluation of the Protein Subunit Vaccine Nanocovax for COVID-19. Frontiers in Immunology, 2021, 12, 766112.	2.2	19
168	Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature, 0, , .	13.7	88
172	Passive immune therapies: another tool against COVID-19. Hematology American Society of Hematology Education Program, 2021, 2021, 628-641.	0.9	9
173	Emergence of SARS-CoV-2 resistance mutations in a patient who received anti-SARS-COV2 spike protein monoclonal antibodies: a case report. BMC Infectious Diseases, 2021, 21, 1223.	1.3	7
174	Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels. Annals of Internal Medicine, 2022, 175, 234-243.	2.0	56
175	Monoclonal antibody therapies in the management of SARS-CoV-2 infection. Expert Opinion on Investigational Drugs, 2022, 31, 41-58.	1.9	26
177	Impact of Casirivimab-Imdevimab on Severe Acute Respiratory Syndrome Coronavirus 2 Delta Variant Nasopharyngeal Virus Load and Spike Quasispecies. Open Forum Infectious Diseases, 2022, 9, ofac093.	0.4	3
178	Significance of Immune Status of SARS-CoV-2 Infected Patients in Determining the Efficacy of Therapeutic Interventions. Journal of Personalized Medicine, 2022, 12, 349.	1.1	3
179	The COVID-19/Tuberculosis Syndemic and Potential Antibody Therapy for TB Based on the Lessons Learnt From the Pandemic. Frontiers in Immunology, 2022, 13, 833715.	2.2	7
180	Mini-review: The market growth of diagnostic and therapeutic monoclonal antibodies – SARS CoV-2 as an example. Human Antibodies, 2022, 30, 15-24.	0.6	10
181	Pharmacogenetics and Precision Medicine Approaches for the Improvement of COVID-19 Therapies. Frontiers in Pharmacology, 2022, 13, 835136.	1.6	17
182	SARS-CoV-2: Recent Variants and Clinical Efficacy of Antibody-Based Therapy. Frontiers in Cellular and Infection Microbiology, 2022, 12, 839170.	1.8	15
183	Lipid nanoparticle-encapsulated mRNA antibody provides long-term protection against SARS-CoV-2 in mice and hamsters. Cell Research, 2022, 32, 375-382.	5.7	21

#	ARTICLE	IF	CITATIONS
184	Antigen-Specific CD4+ T-Cell Activation in Primary Antibody Deficiency After BNT162b2 mRNA COVID-19 Vaccination. <i>Frontiers in Immunology</i> , 2022, 13, 827048.	2.2	16
186	Lipid nanoparticle-mRNA: another step in the fight against COVID-19. <i>Cell Research</i> , 2022, 32, 421-422.	5.7	5
187	Effect of monoclonal antibody therapy on the endogenous SARS-CoV-2 antibody response. <i>Clinical Immunology</i> , 2022, 236, 108959.	1.4	15
188	Deciphering the Neurosensory Olfactory Pathway and Associated Neo-Immunometabolic Vulnerabilities Implicated in COVID-Associated Mucormycosis (CAM) and COVID-19 in a Diabetes Backdrop—A Novel Perspective. <i>International Journal of Diabetology</i> , 2022, 3, 193-235.	0.9	6
190	Short-Term Instantaneous Prophylaxis and Efficient Treatment Against SARS-CoV-2 in hACE2 Mice Conferred by an Intranasal Nanobody (Nb22). <i>Frontiers in Immunology</i> , 2022, 13, 865401.	2.2	8
191	Comprehensive engineering of a therapeutic neutralizing antibody targeting SARS-CoV-2 spike protein to neutralize escape variants. <i>MAbs</i> , 2022, 14, 2040350.	2.6	6
193	In vitro evaluation of therapeutic antibodies against a SARS-CoV-2 Omicron B.1.1.529 isolate. <i>Scientific Reports</i> , 2022, 12, 4683.	1.6	33
195	Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY.4.2. <i>EBioMedicine</i> , 2022, 77, 103934.	2.7	10
196	The SARS-CoV-2 spike reversibly samples an open-trimer conformation exposing novel epitopes. <i>Nature Structural and Molecular Biology</i> , 2022, 29, 229-238.	3.6	81
197	Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617. <i>Nature Communications</i> , 2022, 13, 1638.	5.8	11
198	Biparatopic sybodies neutralize SARS-CoV-2 variants of concern and mitigate drug resistance. <i>EMBO Reports</i> , 2022, 23, e54199.	2.0	30
200	The Effectiveness of the Use of Regdanvimab (CT-P59) in Addition to Remdesivir in Patients with Severe COVID-19: A Single Center Retrospective Study. <i>Tropical Medicine and Infectious Disease</i> , 2022, 7, 51.	0.9	4
201	Tuftsins: A Natural Molecule Against SARS-CoV-2 Infection. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 859162.	1.6	5
202	Augmented neutralization of SARS-CoV-2 Omicron variant by boost vaccination and monoclonal antibodies. <i>European Journal of Immunology</i> , 2022, 52, 970-977.	1.6	10
203	Sulforaphane exhibits antiviral activity against pandemic SARS-CoV-2 and seasonal HCoV-OC43 coronaviruses in vitro and in mice. <i>Communications Biology</i> , 2022, 5, 242.	2.0	42
204	Approaches for the detection and analysis of antidrug antibodies to biopharmaceuticals: A review. <i>Journal of Separation Science</i> , 2022, 45, 2077-2092.	1.3	3
205	Gramicidin S and melittin: potential anti-viral therapeutic peptides to treat SARS-CoV-2 infection. <i>Scientific Reports</i> , 2022, 12, 3446.	1.6	17
206	SARS-CoV-2 Omicron variant: Immune escape and vaccine development. <i>MedComm</i> , 2022, 3, e126.	3.1	74

#	ARTICLE	IF	CITATIONS
207	Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies. <i>Nature Medicine</i> , 2022, 28, 1297-1302.	15.2	235
208	Monobodies with potent neutralizing activity against SARS-CoV-2 Delta and other variants of concern. <i>Life Science Alliance</i> , 2022, 5, e202101322.	1.3	3
209	Successful use of casirivimab/imdevimab anti-spike monoclonal antibodies to enhance neutralizing antibodies in a woman on anti-CD20 treatment with refractory COVID-19. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 991-994.	0.8	4
210	Structure-guided affinity maturation of a single-chain variable fragment antibody against the Fu-bc epitope of the dengue virus envelope protein. <i>Journal of Biological Chemistry</i> , 2022, 298, 101772.	1.6	6
212	Molecular Dynamics and MM-PBSA Analysis of the SARS-CoV-2 Gamma Variant in Complex with the hACE-2 Receptor. <i>Molecules</i> , 2022, 27, 2370.	1.7	10
213	Melatonin and REGN-CoV2 combination as a vaccine adjuvant for Omicron variant of SARS-CoV-2. <i>Molecular Biology Reports</i> , 2022, 49, 4061-4068.	1.0	5
214	The role of antigen-presenting cells in the pathogenesis of COVID-19. <i>Pathology Research and Practice</i> , 2022, 233, 153848.	1.0	17
215	Clinical update on COVID-19 for the emergency and critical care clinician: Medical management. <i>American Journal of Emergency Medicine</i> , 2022, 56, 158-170.	0.7	13
216	ZRC3308 Monoclonal Antibody Cocktail Shows Protective Efficacy in Syrian Hamsters against SARS-CoV-2 Infection. <i>Viruses</i> , 2021, 13, 2424.	1.5	4
217	Monoclonal Antibody Therapy for US Veterans With COVID-19. <i>Infectious Diseases in Clinical Practice</i> , 2022, 30, .	0.1	0
218	Molecular and Clinical Aspects of COVID-19 Vaccines and Other Therapeutic Interventions Apropos Emerging Variants of Concern. <i>Frontiers in Pharmacology</i> , 2021, 12, 778219.	1.6	0
220	Drug repurposing and other strategies for rapid coronavirus antiviral development: lessons from the early stage of the COVID-19 pandemic. , 2021, , 39-68.		0
222	SARS-CoV-2 Therapeutic Landscape, Opportunity and Future Threats. <i>The Open Covid Journal</i> , 2021, 1, 205-215.	0.4	0
224	Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2021, 20, 85.	1.7	23
225	The atomic portrait of SARS-CoV-2 as captured by cryo-electron microscopy. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 25-34.	1.6	6
226	Elucidating T Cell and B Cell Responses to SARS-CoV-2 in Humans: Gaining Insights into Protective Immunity and Immunopathology. <i>Cells</i> , 2022, 11, 67.	1.8	7
227	The effect of casirivimab with imdevimab on disease progression in nonsevere COVID-19 patients in a single hospital in Japan. <i>Journal of General and Family Medicine</i> , 2022, 23, 158-163.	0.3	2
228	Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer. <i>Cancer Discovery</i> , 2022, 12, 303-330.	7.7	24

#	ARTICLE	IF	CITATIONS
229	Development of a Bamlanivimab Infusion Process in the Emergency Department for Outpatient COVID-19 Patients. <i>Healthcare (Switzerland)</i> , 2022, 10, 42.	1.0	3
230	Targeting genomic SARS-CoV-2 RNA with siRNAs allows efficient inhibition of viral replication and spread. <i>Nucleic Acids Research</i> , 2022, 50, 333-349.	6.5	34
232	Coronavirus Entry Inhibitors. <i>Advances in Experimental Medicine and Biology</i> , 2022, 1366, 101-121.	0.8	3
233	Enhanced trimeric ACE2 exhibits potent prophylactic and therapeutic efficacy against the SARS-CoV-2 Delta and Omicron variants in vivo. <i>Cell Research</i> , 2022, 32, 589-592.	5.7	5
234	Coronavirus Disease 2019-Related Alterations of Total and Anti-Spike IgG Glycosylation in Relation to Age and Anti-Spike IgG Titer. <i>Frontiers in Microbiology</i> , 2022, 13, 775186.	1.5	3
235	Peptide-Based Vaccines and Therapeutics for COVID-19. <i>International Journal of Peptide Research and Therapeutics</i> , 2022, 28, 94.	0.9	15
236	Modeling the disruption of respiratory disease clinical trials by non-pharmaceutical COVID-19 interventions. <i>Nature Communications</i> , 2022, 13, 1980.	5.8	5
237	Intramuscular AZD7442 (Tixagevimab&Cilgavimab) for Prevention of Covid-19. <i>New England Journal of Medicine</i> , 2022, 386, 2188-2200.	13.9	450
238	Molecular insights into the differential dynamics of SARS-CoV-2 variants of concern. <i>Journal of Molecular Graphics and Modelling</i> , 2022, 114, 108194.	1.3	21
239	Estimated Health Outcomes and Costs of COVID-19 Prophylaxis With Monoclonal Antibodies Among Unvaccinated Household Contacts in the US. <i>JAMA Network Open</i> , 2022, 5, e228632.	2.8	7
240	Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost. <i>Nature</i> , 2022, 607, 128-134.	13.7	197
242	Anti-Fungal Drug Anidulafungin Inhibits SARS-CoV-2 Spike-Induced Syncytia Formation by Targeting ACE2-Spike Protein Interaction. <i>Frontiers in Genetics</i> , 2022, 13, 866474.	1.1	13
243	SARS-CoV-2: An Overview of the Genetic Profile and Vaccine Effectiveness of the Five Variants of Concern. <i>Pathogens</i> , 2022, 11, 516.	1.2	10
244	Variant-specific vaccination induces systems immune responses and potent in vivo protection against SARS-CoV-2. <i>Cell Reports Medicine</i> , 2022, 3, 100634.	3.3	10
245	Intranasal Lentiviral Vector-Mediated Antibody Delivery Confers Reduction of SARS-CoV-2 Infection in Elderly and Immunocompromised Mice. <i>Frontiers in Immunology</i> , 2022, 13, 819058.	2.2	1
246	Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast?. <i>Nature Reviews Immunology</i> , 2022, 22, 387-397.	10.6	93
247	Comprehensive role of SARS-CoV-2 spike glycoprotein in regulating host signaling pathway. <i>Journal of Medical Virology</i> , 2022, 94, 4071-4087.	2.5	5
248	Immune treatment in COVID-19. <i>Revista Espanola De Quimioterapia</i> , 2022, 35, 59-63.	0.5	3

#	ARTICLE	IF	CITATIONS
249	An overview of current drugs and prophylactic vaccines for coronavirus disease 2019 (COVID-19). Cellular and Molecular Biology Letters, 2022, 27, 38.	2.7	11
250	Biophysical Fitness Landscape of the SARS-CoV-2 Delta Variant Receptor Binding Domain. Journal of Molecular Biology, 2022, 434, 167622.	2.0	3
251	Massively multiplexed affinity characterization of therapeutic antibodies against SARS-CoV-2 variants. Antibody Therapeutics, 2022, 5, 130-137.	1.2	5
252	Real-world clinical outcomes of treatment with casirivimab-imdevimab among patients with mild-to-moderate coronavirus disease 2019 during the Delta variant pandemic. International Journal of Medical Sciences, 2022, 19, 834-841.	1.1	4
253	Risk factors for progression to acute respiratory failure after casirivimab and imdevimab administration: A retrospective study. Respiratory Investigation, 2022, , .	0.9	2
254	Advances in Nanomaterial-Based Platforms to Combat COVID-19: Diagnostics, Preventions, Therapeutics, and Vaccine Developments. ACS Applied Bio Materials, 2022, 5, 2431-2460.	2.3	37
255	Point mutations in SARS-CoV-2 variants induce long-range dynamical perturbations in neutralizing antibodies. Chemical Science, 2022, 13, 7224-7239.	3.7	6
258	Drugs repurposing for SARS-CoV-2: new insight of COVID-19 druggability. Expert Review of Anti-Infective Therapy, 2022, 20, 1187-1204.	2.0	1
260	Therapeutic monoclonal antibodies for COVID-19 management: an update. Expert Opinion on Biological Therapy, 2022, 22, 763-780.	1.4	40
261	A Potent Neutralizing Nanobody Targeting the Spike Receptor-Binding Domain of SARS-CoV-2 and the Structural Basis of Its Intimate Binding. Frontiers in Immunology, 2022, 13, .	2.2	7
262	Conformational Entropy as a Potential Liability of Computationally Designed Antibodies. Biomolecules, 2022, 12, 718.	1.8	8
263	Leveraging South African <sc>HIV</sc> research to define <sc>SARSâ€CoV</sc>â€2 immunity triggered by sequential variants of concern. Immunological Reviews, 2022, 310, 61-75.	2.8	6
264	Current Strategies in Treating Cytokine Release Syndrome Triggered by Coronavirus SARS-CoV-2. ImmunoTargets and Therapy, 0, Volume 11, 23-35.	2.7	3
266	Recent insights into SARSâ€CoVâ€2 omicron variant. Reviews in Medical Virology, 2023, 33, .	3.9	29
267	Atrial fibrillation with aberrant ventricular conduction after receiving Bamlanivimab/Etesevimab: a case report. Current Medical Research and Opinion, 0, , 1-3.	0.9	2
268	Smaller, Stronger, More Stable: Peptide Variants of a SARS-CoV-2 Neutralizing Mini-protein. International Journal of Molecular Sciences, 2022, 23, 6309.	1.8	10
269	A novel high-throughput single B-cell cloning platform for isolation and characterization of high-affinity and potent SARS-CoV-2 neutralizing antibodies. Antiviral Research, 2022, 203, 105349.	1.9	3
270	Immunodetection assays for the quantification of seasonal common cold coronaviruses OC43, NL63, or 229E infection confirm nirmatrelvir as broad coronavirus inhibitor. Antiviral Research, 2022, 203, 105343.	1.9	12

#	ARTICLE	IF	CITATIONS
272	The anti-SARS-CoV-2 monoclonal antibody bamlanivimab minimally affects the endogenous immune response to COVID-19 vaccination. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	19
273	Identification and characterization of the anti-SARS-CoV-2 activity of cationic amphiphilic steroidal compounds. <i>Virulence</i> , 2022, 13, 1031-1048.	1.8	2
274	An Opinion on How Nanobiotechnology is Assisting Humankind to Overcome the Coronavirus Disease 2019. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	0
275	Biologics in COVID-19 So Far: Systematic Review. <i>Pharmaceuticals</i> , 2022, 15, 783.	1.7	5
276	Antibodies to combat viral infections: development strategies and progress. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 676-696.	21.5	68
277	Peptide Antibody Fusions Engineered by Phage Display Exhibit an Ultrapotent and Broad Neutralization of SARS-CoV-2 Variants. <i>ACS Chemical Biology</i> , 2022, 17, 1978-1988.	1.6	7
278	Anti-SARS-CoV2 antibody-mediated cytokine release syndrome in a patient with acute promyelocytic leukemia. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	6
280	Nanoarchitectonics: role of nanomaterials in vaccination strategies for curbing SARS-CoV-2/COVID-19. <i>Nanofabrication</i> , 0, 7, .	1.1	0
281	Broadly Neutralizing Antibodies Against Omicron Variants of SARS-CoV-2 Derived from mRNA-Lipid Nanoparticle-Immunized Mice. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
282	Present therapeutic and diagnostic approaches for SARS-CoV-2 infection. , 2022, , 421-449.		0
284	Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	59
285	Effect of Casirivimab/Imdevimab Treatment on Serum Type I Interferon Levels in SARS-CoV-2 Infection. <i>Viruses</i> , 2022, 14, 1399.	1.5	4
286	Upcoming and urgent challenges in critical care research based on COVID-19 pandemic experience. <i>Anaesthesia, Critical Care &amp; Pain Medicine</i> , 2022, , 101121.	0.6	2
287	Current Therapeutics for COVID-19, What We Know about the Molecular Mechanism and Efficacy of Treatments for This Novel Virus. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7702.	1.8	2
288	Decreased Efficiency of Neutralizing Antibodies from Previously Infected or Vaccinated Individuals against the B.1.617.2 (Delta) SARS-CoV-2 Variant. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	5
289	3D Models as a Tool to Assess the Anti-Tumor Efficacy of Therapeutic Antibodies: Advantages and Limitations. <i>Antibodies</i> , 2022, 11, 46.	1.2	3
290	Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S vaccine in humans. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	10
291	Suppression of SARS-CoV-2 Replication with Stabilized and Click Chemistry Modified siRNAs. <i>Angewandte Chemie - International Edition</i> , 2022, 61, .	7.2	6

#	ARTICLE	IF	CITATIONS
292	New Anti-Flavivirus Fusion Loop Human Antibodies with Zika Virus-Neutralizing Potential. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7805.	1.8	5
293	Suppression of SARS-CoV-2 Replication with Stabilized and Click-Chemistry Modified siRNAs. <i>Angewandte Chemie</i> , 0, , .	1.6	0
294	Respuesta inmune humoral a cuatro vacunas contra el SARS-CoV-2 en profesionales de la salud. <i>Horizonte Médico</i> , 2022, 22, e1937.	0.1	0
295	Antibody-Antigen Binding Interface Analysis in the Big Data Era. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	8
296	Potent neutralizing anti-SARS-CoV-2 human antibodies cure infection with SARS-CoV-2 variants in hamster model. <i>IScience</i> , 2022, 25, 104705.	1.9	8
297	Interactions between COVID-19 and Lung Cancer: Lessons Learned during the Pandemic. <i>Cancers</i> , 2022, 14, 3598.	1.7	7
298	Cas13d knockdown of lung protease Ctsl prevents and treats SARS-CoV-2 infection. <i>Nature Chemical Biology</i> , 2022, 18, 1056-1064.	3.9	26
299	Consensus Clinical Guidance for Diagnosis and Management of Adult COVID-19 Encephalopathy Patients. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2023, 35, 12-27.	0.9	11
300	Characterization of SARS-CoV-2 Escape Mutants to a Pair of Neutralizing Antibodies Targeting the RBD and the NTD. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8177.	1.8	5
302	Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron. <i>Cell Research</i> , 2022, 32, 831-842.	5.7	16
303	Corticosteroids: A boon or bane for COVID-19 patients?. <i>Steroids</i> , 2022, 188, 109102.	0.8	10
304	Monoclonal Antibodies for Pre- and Postexposure Prophylaxis of COVID-19: Review of the Literature. <i>Pathogens</i> , 2022, 11, 882.	1.2	7
305	Co-existence and co-infection of influenza A viruses and coronaviruses: Public health challenges. <i>Innovation (China)</i> , 2022, 3, 100306.	5.2	13
306	A public antibody class recognizes an S2 epitope exposed on open conformations of SARS-CoV-2 spike. <i>Nature Communications</i> , 2022, 13, .	5.8	34
307	A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	15
308	Preclinical assessment and randomized Phase I study of CT-P63, a broadly neutralizing antibody targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). <i>Emerging Microbes and Infections</i> , 2022, 11, 2315-2325.	3.0	3
309	Use of Casirivimab and Imdevimab for the Treatment of COVID-19. <i>Cureus</i> , 2022, , .	0.2	0
310	A multifaceted high-throughput assay for probing antigen-specific antibody-mediated primary monocyte phagocytosis and downstream functions. <i>Journal of Immunological Methods</i> , 2022, 510, 113328.	0.6	3

#	ARTICLE	IF	CITATIONS
311	Functionality of Monoclonal Antibody Therapy in SARS-CoV-2. Journal of Medical Cases, 2022, 13, 380-385.	0.4	0
312	Recent Progress in the Discovery and Development of Monoclonal Antibodies against Viral Infections. Biomedicines, 2022, 10, 1861.	1.4	8
313	Lysine-Targeted Reversible Covalent Ligand Discovery for Proteins via Phage Display. Journal of the American Chemical Society, 2022, 144, 15885-15893.	6.6	21
314	A review of clinical efficacy data supporting emergency use authorization for <scp>COVID</scp> â€19 therapeutics and lessons for future pandemics. Clinical and Translational Science, 0, , .	1.5	2
315	A neutralizing epitope on the SD1 domain of SARS-CoV-2 spike targeted following infection and vaccination. Cell Reports, 2022, 40, 111276.	2.9	29
316	Noninferiority of Subcutaneous Versus Intravenous Casirivimab/Imdevimab for Outpatient Treatment of SARS-CoV-2 in a Real-World Setting. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2022, 41, 210-213.	0.8	0
317	SARSâ€CoVâ€2 Papainâ€Like Protease: Structure, Function and Inhibition. ChemBioChem, 2022, 23, .	1.3	26
318	Perspective Chapter: Tracking Trails of SARS CoV-2 - Variants to Therapy. Infectious Diseases, 0, , .	4.0	0
319	Monoclonal antibodies: a remedial approach to prevent SARS-CoV-2 infection. 3 Biotech, 2022, 12, .	1.1	4
320	Treatment of COVID-19 by monoclonal antibodies and the traditional Chinese medicine. Medicine in Novel Technology and Devices, 2022, 15, 100159.	0.9	0
321	Emerging affinity ligands and support materials for the enrichment of monoclonal antibodies. TrAC - Trends in Analytical Chemistry, 2022, 157, 116744.	5.8	5
322	Beyond the vaccines: a glance at the small molecule and peptide-based anti-COVID19 arsenal. Journal of Biomedical Science, 2022, 29, .	2.6	16
323	Structural basis of a two-antibody cocktail exhibiting highly potent and broadly neutralizing activities against SARS-CoV-2 variants including diverse Omicron sublineages. Cell Discovery, 2022, 8, .	3.1	13
324	Bebtelovimab: considerations for global access to treatments during a rapidly evolving pandemic. Lancet Infectious Diseases, The, 2022, 22, 1531.	4.6	4
325	COVID-19 in patients with B cell immune deficiency. Journal of Immunological Methods, 2022, 510, 113351.	0.6	1
326	Omicron variant: Current insights and future directions. Microbiological Research, 2022, 265, 127204.	2.5	32
327	Monoclonal antibody therapies for COVID-19: lessons learned and implications for the development of future products. Current Opinion in Biotechnology, 2022, 78, 102798.	3.3	14
328	Biotechnological Strategies in the Intervention and Treatment of COVID-19. , 2022, , 421-442.		1



#	ARTICLE	IF	CITATIONS
329	Mapping monoclonal anti-SARS-CoV-2 antibody repertoires against diverse coronavirus antigens. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
330	Comprehensive studies on building a scalable downstream process for <scp>mRNAs</scp> to enable <scp>mRNA</scp> therapeutics. <i>Biotechnology Progress</i> , 2023, 39, .	1.3	6
331	Screening and Characterization of Shark-Derived VNARs against SARS-CoV-2 Spike RBD Protein. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10904.	1.8	8
332	Engineering SARS-CoV-2 specific cocktail antibodies into a bispecific format improves neutralizing potency and breadth. <i>Nature Communications</i> , 2022, 13, .	5.8	16
333	A Systematic Review on the Emergence of Omicron Variant and Recent Advancement in Therapies. <i>Vaccines</i> , 2022, 10, 1468.	2.1	7
334	Sustained Delivery of a Monoclonal Antibody against SARS-CoV-2 by Microencapsulated Cells: A Proof-of-Concept Study. <i>Pharmaceutics</i> , 2022, 14, 2042.	2.0	0
335	Mucosal nanobody IgA as inhalable and affordable prophylactic and therapeutic treatment against SARS-CoV-2 and emerging variants. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
336	Single-cell analysis of the adaptive immune response to SARS-CoV-2 infection and vaccination. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
337	Long-term memory CD8+ T cells specific for SARS-CoV-2 in individuals who received the BNT162b2 mRNA vaccine. <i>Nature Communications</i> , 2022, 13, .	5.8	11
338	Mixed-dimensional multi-scale poroelastic modeling of adipose tissue for subcutaneous injection. <i>Biomechanics and Modeling in Mechanobiology</i> , 2022, 21, 1825-1840.	1.4	6
339	Seroconversion rate after COVID-19 vaccination in patients with solid cancer: A systematic review and meta-analysis. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	5
340	Current clinical status of new COVID-19 vaccines and immunotherapy. <i>Environmental Science and Pollution Research</i> , 0, , .	2.7	5
341	Therapeutic Role of Neutralizing Antibody for the Treatment against SARS-CoV-2 and Its Emerging Variants: A Clinical and Pre-Clinical Perspective. <i>Vaccines</i> , 2022, 10, 1612.	2.1	14
342	The Receptor Binding Domain of SARS-CoV-2 Lambda Variant Has a Better Chance Than the Delta Variant in Evading BNT162b2 COVID-19 mRNA Vaccine-Induced Humoral Immunity. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11325.	1.8	6
343	Recent Drug Development and Medicinal Chemistry Approaches for the Treatment of SARS-CoV-2 Infection and COVID-19. <i>ChemMedChem</i> , 2022, 17, .	1.6	33
344	Failed clinical trials on COVID-19 acute respiratory distress syndrome in hospitalized patients: common oversights and streamlining the development of clinically effective therapeutics. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 995-1015.	1.9	4
346	A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	64
347	An efficient approach for SARS-CoV-2 monoclonal antibody production via modified mRNA-LNP immunization. <i>International Journal of Pharmaceutics</i> , 2022, 627, 122256.	2.6	8

#	ARTICLE	IF	CITATIONS
348	Recent advances and persistent challenges in the design of freeze-drying process for monoclonal antibodies. <i>Pharmaceutical Development and Technology</i> , 2022, 27, 942-955.	1.1	1
349	Biparatopic nanobodies targeting the receptor binding domain efficiently neutralize SARS-CoV-2. <i>IScience</i> , 2022, 25, 105259.	1.9	4
350	Managing Covid-19 in patients with heart failure: current status and future prospects. <i>Expert Review of Cardiovascular Therapy</i> , 2022, 20, 807-828.	0.6	0
351	Lucidenic acid A inhibits the binding of hACE2 receptor with spike protein to prevent SARS-CoV-2 invasion. <i>Food and Chemical Toxicology</i> , 2022, 169, 113438.	1.8	3
352	Supported Natural Membranes on Microspheres for Protein-Protein Interaction Studies. <i>ACS Applied Materials &amp; Interfaces</i> , 2022, 14, 49532-49541.	4.0	6
353	Long-term cellular immune response in immunocompromised unvaccinated COVID-19 patients undergoing monoclonal antibody treatment. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
355	Membrane attachment and fusion of HIV-1, influenza A, and SARS-CoV-2: resolving the mechanisms with biophysical methods. <i>Biophysical Reviews</i> , 2022, 14, 1109-1140.	1.5	15
356	Efficacy and safety of sotrovimab in patients with COVID-19: A rapid review and meta-analysis. <i>Reviews in Medical Virology</i> , 2022, 32, .	3.9	17
357	SARS-CoV-2 variants of concern and spike protein mutational dynamics in a Swedish cohort during 2021, studied by Nanopore sequencing. <i>Virology Journal</i> , 2022, 19, .	1.4	5
358	A guide to COVID-19 antiviral therapeutics: a summary and perspective of the antiviral weapons against SARS-CoV-2 infection. <i>FEBS Journal</i> , 0, , .	2.2	6
359	COVID-19 and Gut Injury. <i>Nutrients</i> , 2022, 14, 4409.	1.7	8
360	SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies. <i>Nature Reviews Microbiology</i> , 2023, 21, 112-124.	13.6	128
361	Therapeutic advances in COVID-19. <i>Nature Reviews Nephrology</i> , 2023, 19, 38-52.	4.1	67
362	Efficacy of COVID-HiGIV in animal models of SARS-CoV-2 infection. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
363	Rapid Generation of Circulating and Mucosal Decoy Human ACE2 using mRNA Nanotherapeutics for the Potential Treatment of SARS-CoV-2. <i>Advanced Science</i> , 2022, 9, .	5.6	17
364	Clinical course of SARS-CoV-2 infection and recovery in lung transplant recipients. <i>Transplant Infectious Disease</i> , 2022, 24, .	0.7	4
365	Neutralizing antibodies for SARS-CoV-2 infection. <i>Revista Espanola De Quimioterapia</i> , 2022, 35, 16-19.	0.5	0
366	Neutralizing Ability of a Single Domain VNAR Antibody: In Vitro Neutralization of SARS-CoV-2 Variants of Concern. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12267.	1.8	9

#	ARTICLE	IF	CITATIONS
367	Recent review of COVID-19 management: diagnosis, treatment and vaccination. <i>Pharmacological Reports</i> , 2022, 74, 1120-1148.	1.5	37
368	What Is New in Prophylaxis and Treatment of COVID-19 in Renal Transplant Patients? A Report from an ESOT Meeting on the Topic. <i>Transplantology</i> , 2022, 3, 288-306.	0.3	0
369	SARS-CoV-2 spike opening dynamics and energetics reveal the individual roles of glycans and their collective impact. <i>Communications Biology</i> , 2022, 5, .	2.0	37
370	Cartography of SARS-CoV-2 variants based on the susceptibility to therapeutic monoclonal antibodies. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	1
371	Broad-Spectrum Virus Trapping with Heparan Sulfate-Modified DNA Origami Shells. <i>ACS Nano</i> , 2022, 16, 20002-20009.	7.3	11
372	Rational Development of Hypervalent Glycan Shield-Binding Nanoparticles with Broad-Spectrum Inhibition against Fatal Viruses Including SARS-CoV-2 Variants. <i>Advanced Science</i> , 2023, 10, .	5.6	10
373	Multimeric ACE2-IgM fusions as broadly active antivirals that potently neutralize SARS-CoV-2 variants. <i>Communications Biology</i> , 2022, 5, .	2.0	8
374	Antigenic mapping reveals sites of vulnerability on HCoV spike protein. <i>Communications Biology</i> , 2022, 5, .	2.0	2
375	Decrease in serum levels of autotaxin in COVID-19 patients. <i>Annals of Medicine</i> , 2022, 54, 3188-3199.	1.5	1
376	Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in patients in the community: observational cohort study with the OpenSAFELY platform. <i>BMJ</i> , The, 0, , e071932.	3.0	42
377	Immune repertoire profiling for disease pathobiology. <i>Pathology International</i> , 2023, 73, 1-11.	0.6	1
378	Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2 specific memory T cell responses. <i>JCI Insight</i> , 2022, 7, .	2.3	5
379	Producing Biologics with Defined N-Glycosylation in Plants. <i>Methods in Molecular Biology</i> , 2023, , 235-250.	0.4	1
381	Persistence of neutralizing antibodies and clinical protection up to 12 months after SARS-CoV-2 infection in elderly. <i>Open Forum Infectious Diseases</i> , 0, , .	0.4	0
382	Potent SARS-CoV-2 neutralizing antibodies with therapeutic effects in two animal models. <i>IScience</i> , 2022, 25, 105596.	1.9	8
383	Current Insights and Molecular Docking Studies of the Drugs under Clinical Trial as RdRp Inhibitors in COVID-19 Treatment. <i>Current Pharmaceutical Design</i> , 2022, 28, 3677-3705.	0.9	6
386	Investigating RNA-protein recognition mechanisms through supervised molecular dynamics (SuMD) simulations. <i>NAR Genomics and Bioinformatics</i> , 2022, 4, .	1.5	6
387	Efficacy and Safety of Nirmatrelvir/Ritonavir, Molnupiravir, and Remdesivir in a Real-World Cohort of Outpatients with COVID-19 at High Risk of Progression: The PISA Outpatient Clinic Experience. <i>Infectious Diseases and Therapy</i> , 2023, 12, 257-271.	1.8	26

#	ARTICLE	IF	CITATIONS
388	Structural Insight into the Resistance of the SARS-CoV-2 Omicron BA.4 and BA.5 Variants to Cilgavimab. <i>Viruses</i> , 2022, 14, 2677.	1.5	8
389	Simultaneous measurement of multiple variant-specific SARS-CoV-2 neutralizing antibodies with a multiplexed flow cytometric assay. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
390	Antiviral Treatment of COVID-19 Pneumonia. <i>Clinics in Chest Medicine</i> , 2022, , .	0.8	0
391	RNA G-quadruplex forming regions from SARS-2, SARS-1 and MERS coronaviruses. <i>Frontiers in Chemistry</i> , 0, 10, .	1.8	5
392	Efficacy and Safety of Tixagevimab/Cilgavimab to Prevent COVID-19 (Pre-Exposure Prophylaxis): A Systematic Review and Meta-Analysis. <i>Diseases (Basel, Switzerland)</i> , 2022, 10, 118.	1.0	11
393	SARS-CoV-2 proteases Mpro and PLpro: Design of inhibitors with predicted high potency and low mammalian toxicity using artificial neural networks, ligand-protein docking, molecular dynamics simulations, and ADMET calculations. <i>Computers in Biology and Medicine</i> , 2023, 153, 106449.	3.9	9
394	Roles of RNA-binding proteins in neurological disorders, COVID-19, and cancer. <i>Human Cell</i> , 2023, 36, 493-514.	1.2	2
395	Tixagevimab Plus Cilgavimab Does Not Affect the Interpretation of Electrophoretic and Free Light Chain Assays. <i>American Journal of Clinical Pathology</i> , 0, , .	0.4	0
396	Overcoming Biopharmaceutical Interferents for Quantitation of Host Cell DNA Using an Automated, High-Throughput Methodology. <i>AAPS Journal</i> , 2023, 25, .	2.2	0
397	Computational framework for the techno-economic analysis of monoclonal antibody capture chromatography platforms. <i>Journal of Chromatography A</i> , 2023, 1689, 463755.	1.8	2
398	A bispecific nanobody dimer broadly neutralizes SARS-CoV-1 & 2 variants of concern and offers substantial protection against Omicron via low-dose intranasal administration. <i>Cell Discovery</i> , 2022, 8, .	3.1	12
399	The D614G mutation redirects SARS-CoV-2 spike to lysosomes and suppresses deleterious traits of the furin cleavage site insertion mutation. <i>Science Advances</i> , 2022, 8, .	4.7	5
401	Critical review of conformational B-cell epitope prediction methods. <i>Briefings in Bioinformatics</i> , 2023, 24, .	3.2	14
402	Emerging Methods in Biosensing of Immunoglobulin Gâ€™A Review. <i>Sensors</i> , 2023, 23, 676.	2.1	3
403	Fluorogenic reporter enables identification of compounds that inhibit SARS-CoV-2. <i>Nature Microbiology</i> , 2023, 8, 121-134.	5.9	6
405	Intermediate Levels of Pre-Existing Protective Antibody Allow Priming of Protective T Cell Immunity against Influenza. <i>Journal of Immunology</i> , 2023, 210, 628-639.	0.4	1
406	Cross-immunity against SARS-COV-2 variants of concern in naturally infected critically ill COVID-19 patients. <i>Heliyon</i> , 2023, 9, e12704.	1.4	2
407	A Review of the Currently Available Antibody Therapy for the Treatment of Coronavirus Disease 2019 (COVID-19). <i>Antibodies</i> , 2023, 12, 5.	1.2	15

#	ARTICLE	IF	CITATIONS
408	Identification of a short ACE2-derived stapled peptide targeting the SARS-CoV-2 spike protein. <i>European Journal of Medicinal Chemistry</i> , 2023, 249, 115118.	2.6	6
409	A simple in-host model for COVID-19 with treatments: model prediction and calibration. <i>Journal of Mathematical Biology</i> , 2023, 86, .	0.8	2
410	Applications of nanobodies in the prevention, detection, and treatment of the evolving SARS-CoV-2. <i>Biochemical Pharmacology</i> , 2023, 208, 115401.	2.0	5
411	A review on "monoclonal antibodies: effective treatment against COVID-19". <i>International Journal of Community Medicine and Public Health</i> , 2022, 10, 525.	0.0	0
412	Manufacture and Characterization of Good Manufacturing Practice-Compliant SARS-COV-2 Cytotoxic T Lymphocytes. <i>Journal of Infectious Diseases</i> , 0, , .	1.9	0
414	Exploring the Role of Immune System and Inflammatory Cytokines in SARS-CoV-2 Induced Lung Disease: A Narrative Review. <i>Biology</i> , 2023, 12, 177.	1.3	11
415	The burden of hospitalisations for COVID-19 in France: a study of all cases in the national insurance claims database in 2020. <i>Journal of Market Access &amp; Health Policy</i> , 2023, 11, .	0.8	1
416	Emerging technologies for COVID-19, diagnosis, prevention, and management. , 2023, , 389-404.		1
417	Impacts of viral pathogenesis and vaccine immunization on the host humoral immune response in SARS-CoV-2 and associated variants of concern (VOCs) infection. , 2023, , 237-262.		0
418	Functional nucleic acids as potent therapeutics against SARS-CoV-2 infection. <i>Cell Reports Physical Science</i> , 2023, , 101249.	2.8	1
419	Antibody accessibility determines location of spike surface mutations in SARS-CoV-2 variants. <i>PLoS Computational Biology</i> , 2023, 19, e1010822.	1.5	4
421	Comparative Binding Ability of Human Monoclonal Antibodies against Omicron Variants of SARS-CoV-2: An In Silico Investigation. <i>Antibodies</i> , 2023, 12, 17.	1.2	6
422	Experience in the use of neutralizing monoclonal antibodies in kidney transplant recipients with COVID-19. <i>Vestnik Transplantologii i Iskusstvennykh Organov</i> , 2023, 25, 7-14.	0.1	0
423	19n01, a broadly neutralizing antibody against omicron BA.1, BA.2, BA.4/5, and other SARS-CoV-2 variants of concern. <i>IScience</i> , 2023, 26, 106562.	1.9	1
424	Convalescent plasma (hyperimmune immunoglobulin) for COVID-19 management: An update. <i>Process Biochemistry</i> , 2023, 127, 66-81.	1.8	9
425	A Potent Recombinant Polyclonal Antibody Therapeutic for Protection Against New SARS-CoV-2 Variants of Concern. <i>Journal of Infectious Diseases</i> , 0, , .	1.9	1
426	Casirivimab/imdevimab + remdesivir in hospitalized patients with severe Covid-19: A single centre experience. <i>Heliyon</i> , 2023, 9, e13126.	1.4	1
427	Novel Strategy for Alzheimer's Disease Treatment through Oral Vaccine Therapy with Amyloid Beta. <i>Biologics</i> , 2023, 3, 23-39.	2.3	0

#	ARTICLE	IF	CITATIONS
428	High-throughput saturation mutagenesis generates a high-affinity antibody against SARS-CoV-2 variants using protein surface display assay on a human cell. <i>PLoS Pathogens</i> , 2023, 19, e1011119.	2.1	2
429	Host immunological responses facilitate development of SARS-CoV-2 mutations in patients receiving monoclonal antibody treatments. <i>Journal of Clinical Investigation</i> , 2023, 133, .	3.9	16
430	Association of subpleural ground-glass opacities with respiratory failure and RNAemia in COVID-19. <i>European Radiology</i> , 2023, 33, 4713-4722.	2.3	2
431	The Role of Cyclodextrins in COVID-19 Therapy”A Literature Review. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2974.	1.8	8
432	A Competitive Panning Method Reveals an Anti-SARS-CoV-2 Nanobody Specific for an RBD-ACE2 Binding Site. <i>Vaccines</i> , 2023, 11, 371.	2.1	3
433	An overview on the treatments and prevention against COVID-19. <i>Virology Journal</i> , 2023, 20, .	1.4	19
434	Immunogenicity of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in SARS-CoV-2-naïve and exposed individuals in a phase 2/3, double-blind, randomized study. <i>Vaccine</i> , 2023, 41, 1875-1884.	1.7	7
435	Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies. <i>Nature Communications</i> , 2023, 14, .	5.8	87
437	Plants as Biofactories for Therapeutic Proteins and Antiviral Compounds to Combat COVID-19. <i>Life</i> , 2023, 13, 617.	1.1	5
438	Safety and Biodistribution of Nanoligomers Targeting the SARS-CoV-2 Genome for the Treatment of COVID-19. <i>ACS Biomaterials Science and Engineering</i> , 2023, 9, 1656-1671.	2.6	10
439	COVID-19 Therapeutics: Use, Mechanism of Action, and Toxicity (Vaccines, Monoclonal Antibodies, and) Tj ETQq0 0.0 rgBT /Overlock 10	0.8	8
440	Applications and prospects of cryo-EM in drug discovery. <i>Military Medical Research</i> , 2023, 10, .	1.9	2
441	COVID-19 spike polypeptide vaccine reduces the pathogenesis and viral infection in a mouse model of SARS-CoV-2. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
443	Preclinical evaluation of ISH0339, a tetravalent broadly neutralizing bispecific antibody against SARS-CoV-2 with long-term protection. <i>Antibody Therapeutics</i> , 2023, 6, 97-107.	1.2	0
444	Importance, Applications and Features of Assays Measuring SARS-CoV-2 Neutralizing Antibodies. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5352.	1.8	7
445	Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineages. <i>IScience</i> , 2023, 26, 106413.	1.9	13
446	Surrogate-based optimization of capture chromatography platforms for the improvement of computational efficiency. <i>Computers and Chemical Engineering</i> , 2023, 173, 108225.	2.0	0
447	Drug discovery processes: When and where the rubber meets the road. , 2023, , 339-415.		1

#	ARTICLE	IF	CITATIONS
448	Identifying promising druggable binding sites and their flexibility to target the receptor-binding domain of SARS-CoV-2 spike protein. Computational and Structural Biotechnology Journal, 2023, 21, 2339-2351.	1.9	5
449	Highly Selective Aptamer-Molecularly Imprinted Polymer Hybrids for Recognition of SARS-CoV-2 Spike Protein Variants. Global Challenges, 2023, 7, .	1.8	0
450	Endemic, epidemic and pandemic infections: the roles of natural and acquired herd immunity. Current Opinion in Infectious Diseases, 2023, 36, 171-176.	1.3	3
451	Plant-based biopharmaceutical engineering. , 2023, 1, 426-439.		24
452	Chemical conjugation to differentiate monosaccharides by Raman and surface enhanced Raman spectroscopy. Analyst, The, 2023, 148, 2035-2044.	1.7	1
454	Arterial hypertension in COVID-19. Klinicheskaia Meditsina, 2023, 101, 26-31.	0.2	1
455	Understanding Mutations in Human SARS-CoV-2 Spike Glycoprotein: A Systematic Review & Meta-Analysis. Viruses, 2023, 15, 856.	1.5	10
456	Clinical Characteristics of SARS-CoV-2 Omicron Cases in Pune, Maharashtra, India. Cureus, 2023, , .	0.2	0
457	Competitive Adsorption of a Monoclonal Antibody and Nonionic Surfactant at the PDMS/Water Interface. Molecular Pharmaceutics, 2023, 20, 2502-2512.	2.3	2
458	Therapeutics for COVID-19. , 2024, , 282-307.		0
459	COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery. Genes and Diseases, 2023, , .	1.5	3
460	Extrinsic stabilization of antiviral ACE2-Fc fusion proteins targeting SARS-CoV-2. Communications Biology, 2023, 6, .	2.0	3
461	Potent Omicron-neutralizing antibodies isolated from a patient vaccinated 6 months before Omicron emergence. Cell Reports, 2023, 42, 112421.	2.9	3
462	Rapid engineering of SARS-CoV-2 therapeutic antibodies to increase breadth of neutralization including BQ.1.1, CA.3.1, CH.1.1, XBB.1.16, and XBB.1.5. Antibody Therapeutics, 2023, 6, 108-118.	1.2	1
463	A quantitative systems pharmacology model of the pathophysiology and treatment of COVID-19 predicts optimal timing of pharmacological interventions. Npj Systems Biology and Applications, 2023, 9, .	1.4	3
464	Broadly neutralizing antibodies against Omicron variants of SARS-CoV-2 derived from mRNA-lipid nanoparticle-immunized mice. Heliyon, 2023, 9, e15587.	1.4	1
465	Therapeutic strategies for COVID-19: progress and lessons learned. Nature Reviews Drug Discovery, 2023, 22, 449-475.	21.5	112
466	Editorial: Porcine reproductive and respiratory syndrome virus - animal virology, immunology, and pathogenesis. Frontiers in Immunology, 0, 14, .	2.2	1

#	ARTICLE	IF	CITATIONS
467	Specific Activation of T Cells by an ACE2-Based CAR-Like Receptor upon Recognition of SARS-CoV-2 Spike Protein. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7641.	1.8	4
483	The Dawn of a New Era: Targeting the "Undruggables" with Antibody-Based Therapeutics. <i>Chemical Reviews</i> , 2023, 123, 7782-7853.	23.0	13
490	Coronavirus Vaccines. , 2023, , 248-257.e4.		0
495	Site-specific drug delivery utilizing monoclonal antibodies. , 2023, , 649-681.		0
500	Single B-cell sequencing in monoclonal antibody discovery. , 2024, , 73-95.		0
503	Interaction of SARS-CoV-2 with host cells and antibodies: experiment and simulation. <i>Chemical Society Reviews</i> , 2023, 52, 6497-6553.	18.7	1
515	Small molecule and biological drugs for treatment of COVID-19. , 2023, , .		0
516	Antibody Batch Cloning. <i>Methods in Molecular Biology</i> , 2023, , 411-417.	0.4	0
527	Association study between killer immunoglobulin-like receptor polymorphisms and susceptibility to COVID-19 disease: a systematic review and meta-analysis. <i>Immunologic Research</i> , 0, , .	1.3	0
534	Passive antibody therapy in emerging infectious diseases. <i>Frontiers of Medicine</i> , 2023, 17, 1117-1134.	1.5	2
555	CHITV: an updated combination treatment regimen for COVID-19. , 2024, , 2743-2751.		0